For example, pembrolizumab is administered with chemotherapy for NSCLC, trastuzumab is combined with pertuzumab for HER2‐positive breast cancer, bevacizumab is combined with chemotherapy for metastatic colorectal cancer, and bortezomib is used with dexamethasone for multiple myeloma [378, 379, 380, 381]. The gene discussed is ERBB2; the disease is plasma cell myeloma.